Ozempic vs Wegovy vs Mounjaro vs Trulicity (2026): Evidence-Based Comparison of GLP-1 Weight Loss Drugs
Updated October 2026 · This article focuses on the weekly injectable products. U.S. FDA indications are used for the regulatory comparison; availability, brand names, dosing and approvals can differ in Malaysia and other countries.
Ozempic, Wegovy, Mounjaro and Trulicity are not simply four versions of the same drug. Ozempic and Wegovy contain semaglutide; Mounjaro contains tirzepatide; and Trulicity contains dulaglutide. The most important pharmacologic difference is that tirzepatide activates both GIP and GLP-1 receptors, whereas the other three are GLP-1 receptor agonists.
For weight loss, the 2026 picture is more nuanced than it was a few years ago. Tirzepatide has produced greater average weight loss than semaglutide in a direct head-to-head obesity trial. At the same time, semaglutide has moved into a new phase with Wegovy HD 7.2 mg, approved by the U.S. FDA in March 2026 for additional weight reduction in appropriate adults.
Ozempic vs Wegovy vs Mounjaro vs Trulicity: Quick Comparison
Ozempic
Wegovy
Mounjaro
Trulicity
Maximum doses depend on indication, titration, tolerance and current regulatory labeling.
The First Big Difference: GLP-1 vs GIP + GLP-1
Ozempic, Wegovy and Trulicity are GLP-1 receptor agonists. GLP-1 signaling can increase glucose-dependent insulin secretion, decrease glucagon secretion, slow gastric emptying and reduce appetite.
.png "Best Weight Loss Peptides")
Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors, producing strong effects on glucose control, appetite and body weight.
This difference is one reason tirzepatide has generated particularly large weight-loss and HbA1c reductions in clinical trials. It does not mean that dual agonism is automatically better for every patient; tolerability, comorbidities, treatment goals, access and insurance coverage all matter.
Ozempic vs Wegovy: Same Molecule, Different Jobs
One of the most common misconceptions is that Ozempic and Wegovy are different active drugs.
They are not.
Both contain semaglutide. The major distinction is the product's approved indication and dosing strategy.
Ozempic
Wegovy
2026 Update: Wegovy HD 7.2 mg Changes the Weight-Loss Comparison
Older GLP-1 articles often state that Wegovy's highest dose is 2.4 mg weekly. That is no longer fully current in the United States.
In March 2026, the FDA approved Wegovy HD 7.2 mg for additional weight reduction in adults with obesity or overweight plus a weight-related condition.
In the STEP UP trial, adults with obesity but without type 2 diabetes experienced approximately 18.7% mean weight loss with semaglutide 7.2 mg under the study's treatment-regimen analysis, compared with approximately 15.6% with semaglutide 2.4 mg and 3.9% with placebo.
These results should not be compared directly with the SURMOUNT-5 tirzepatide results as though they came from the same trial.
Mounjaro vs Wegovy for Weight Loss
The scientifically cleaner comparison for obesity is usually tirzepatide vs semaglutide, because Mounjaro is the U.S. tirzepatide brand labeled for type 2 diabetes, while Zepbound is the U.S. tirzepatide product specifically approved for chronic weight management.
The landmark SURMOUNT-5 randomized trial directly compared tirzepatide with semaglutide in adults with overweight or obesity who did not have diabetes.
SURMOUNT-5: Mean Weight Loss
Tirzepatide produced approximately 20.2% mean weight loss at 72 weeks compared with 13.7% with semaglutide.
Tirzepatide
Semaglutide
Critical caveat: SURMOUNT-5 compared tirzepatide with semaglutide doses up to 2.4 mg. It did not compare tirzepatide directly against the newer 7.2-mg Wegovy HD dose.
Which Is Better for Type 2 Diabetes?
For diabetes, the question is not simply “Which causes more weight loss?” HbA1c lowering, hypoglycemia risk, cardiovascular disease, kidney disease, other medications and treatment goals all matter.
The strongest direct comparison among these molecules comes from SURPASS-2, which compared tirzepatide 5 mg, 10 mg and 15 mg with semaglutide 1 mg in patients with type 2 diabetes receiving background metformin.
Tirzepatide 5 mg
Tirzepatide 10 mg
Tirzepatide 15 mg
Semaglutide 1 mg
In SURPASS-2, all three tirzepatide doses produced greater HbA1c reduction than semaglutide 1 mg. Weight loss was also greater with tirzepatide.
Where Does Trulicity Fit?
Trulicity contains dulaglutide, another once-weekly GLP-1 receptor agonist.
Trulicity is primarily a diabetes medicine. Its U.S. label includes improvement of glycemic control in adults and children aged 10 years and older with type 2 diabetes and reduction of major cardiovascular events in appropriate adults with type 2 diabetes.
It can cause weight loss, but its weight-loss effect has generally been more modest than the larger reductions seen with modern obesity-dose semaglutide or tirzepatide.
AWARD-11
Average weight reduction at 36 weeks with dulaglutide 4.5 mg in adults with type 2 diabetes.
Weight-Loss Evidence at a Glance
Wegovy 2.4 mg — STEP 1
Wegovy HD 7.2 mg — STEP UP
Tirzepatide — SURMOUNT-5
Trulicity 4.5 mg — AWARD-11
Do not treat these figures as a simple league table. The trials had different populations, durations, background treatments, doses and statistical methods.
Which Drug Is Best for Weight Loss?
For someone whose primary goal is substantial weight reduction, the current evidence points toward tirzepatide as the strongest option among these molecules based on direct comparison with semaglutide 2.4 mg.
But there is an important 2026 qualification:
Wegovy HD 7.2 mg substantially improves the semaglutide weight-loss profile compared with Wegovy 2.4 mg.
Because there is no direct randomized trial of tirzepatide 10/15 mg versus Wegovy 7.2 mg, it is premature to declare a definitive winner between maximum-dose tirzepatide and maximum-dose semaglutide HD.
Which Is Best for Diabetes?
Strong glucose lowering + weight reduction
Dual GIP/GLP-1 agonism is associated with strong HbA1c and body-weight effects in SURPASS trials.
T2D + established cardiovascular disease
Both have cardiovascular-risk-reduction indications in appropriate adults with type 2 diabetes.
T2D + chronic kidney disease
Its current U.S. label includes a kidney and cardiovascular risk-reduction indication in adults with T2D and CKD.
Obesity is the central treatment target
These products have specific obesity-focused indications.
Established diabetes therapy that is already working
Switching solely to chase a larger average trial result is not automatically better for an individual patient.
Ozempic vs Wegovy vs Mounjaro vs Trulicity Dosing
Ozempic
Wegovy
Mounjaro
Trulicity
Higher dose does not automatically mean better treatment. Dose escalation is generally gradual because gastrointestinal adverse effects are often most noticeable during initiation and dose increases.
Common Side Effects
Ozempic
Wegovy
Mounjaro
Trulicity
Exact adverse-effect frequencies vary by dose and trial. Gastrointestinal symptoms are often most prominent during titration and may improve with continued treatment.
Important Safety Issues
Thyroid C-cell tumor warning
Ozempic, Wegovy, Mounjaro and Trulicity all carry boxed warnings concerning thyroid C-cell tumors based on findings in rodents. Human relevance remains unknown.
These drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis
Acute pancreatitis has been observed with GLP-1 receptor agonists and tirzepatide. Persistent or severe abdominal pain, particularly pain that may radiate to the back, warrants urgent medical evaluation.
Gallbladder disease
Gallstones and cholecystitis can occur. Rapid weight loss itself can also increase gallstone risk.
Gastroparesis and gastrointestinal disease
These medications slow gastric emptying to varying degrees. Current labels warn about severe gastrointestinal reactions, and some products are not recommended in patients with severe gastroparesis.
Hypoglycemia
GLP-1-based drugs generally have a lower intrinsic risk of hypoglycemia than insulin or some insulin-secretagogue drugs. However, the risk can increase when they are combined with insulin or sulfonylureas/other insulin secretagogues.
Dehydration and kidney injury
Severe nausea, vomiting or diarrhea can result in dehydration and acute kidney injury. This is particularly relevant during dose escalation.
Surgery and anesthesia
Patients should tell their surgical and anesthesia teams that they are taking a GLP-1 or GIP/GLP-1 medicine because current prescribing information includes warnings concerning pulmonary aspiration during general anesthesia or deep sedation.
What About Muscle Loss?
Weight loss from GLP-1 and GIP/GLP-1 therapies can include both fat mass and lean mass. The goal should therefore not be to maximize the number on the scale as quickly as possible.
A better strategy combines medication with:
- adequate protein intake;
- resistance training;
- appropriate calorie intake rather than extreme restriction;
- adequate micronutrient intake; and
- monitoring of body composition, strength and physical function where appropriate.
What Happens When You Stop?
These medications are generally considered treatments for chronic metabolic disease rather than short-term “diet shots.” When treatment is stopped, appetite and metabolic signals can move back toward the patient's pretreatment state, and weight regain is common.
That is why maintenance therapy is increasingly important in obesity medicine.
The 2026 Ranking: A Better Way to Think About It
Weight loss — direct head-to-head evidence
20.2% vs 13.7% for semaglutide 2.4 mg in SURMOUNT-5.
Semaglutide's newer weight-loss ceiling
Higher-dose semaglutide became available in the U.S. in 2026 for selected adults.
Type 2 diabetes glucose lowering
Superior HbA1c reduction versus semaglutide 1 mg in SURPASS-2.
T2D + CKD labeled kidney benefit
Specific FDA-labeled kidney and cardiovascular outcome reduction.
T2D cardiovascular outcome evidence
Both have established cardiovascular outcomes indications in appropriate T2D populations.
Obesity-specific semaglutide
Specifically labeled for chronic weight management, including the newer higher-dose 7.2-mg option for selected adults in the United States.
Final Verdict
For weight loss, tirzepatide currently has the strongest direct comparative evidence, but the 2026 approval of Wegovy HD 7.2 mg makes the comparison more competitive than older articles suggest.
For type 2 diabetes, tirzepatide generally delivers stronger average HbA1c and weight reductions than semaglutide in direct comparison trials, but Ozempic and Trulicity have important cardiovascular and/or kidney outcome evidence that can change the clinical decision.
Ozempic and Wegovy are the same molecule—semaglutide—but different branded products with different FDA indications and dosing frameworks.
Mounjaro and Zepbound contain the same active ingredient—tirzepatide—but are marketed for different indications in the United States.
Trulicity remains an established evidence-based diabetes treatment, but it generally should not be selected primarily because of weight-loss expectations.
The most important lesson is that there is no universal “best GLP-1 drug.” The best medication is the one that fits the patient's diagnosis, treatment goal, cardiovascular and kidney risk, tolerability, other medications, cost/access and long-term adherence.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
Tirzepatide generally produces greater average weight loss than semaglutide in direct clinical comparisons. Mounjaro is the U.S. diabetes brand, while Zepbound is the U.S. tirzepatide product specifically approved for chronic weight management.
Are Ozempic and Wegovy the same drug?
Yes. Both contain semaglutide. Their major differences are the approved indications, branded products and dosing frameworks.
Is Wegovy stronger than Ozempic?
For obesity treatment, Wegovy is the semaglutide product specifically labeled for chronic weight management. In 2026, selected adults may also receive Wegovy HD 7.2 mg after tolerating 2.4 mg.
Does Trulicity cause weight loss?
Yes. Dulaglutide can produce weight reduction, although the average effect has generally been more modest than the larger weight reductions reported with obesity-dose semaglutide and tirzepatide.
Can you take Ozempic and Wegovy together?
No. They contain the same active ingredient, semaglutide, and the current Wegovy labeling does not recommend using it with other semaglutide-containing products or other GLP-1 receptor agonists.
Which is better for type 2 diabetes: Mounjaro or Ozempic?
In SURPASS-2, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg. However, Ozempic has specific cardiovascular and kidney outcome indications that may be particularly important for selected patients.
Is Wegovy HD 7.2 mg available in 2026?
Yes. The U.S. FDA approved Wegovy HD 7.2 mg in March 2026 for additional weight reduction in appropriate adults. Availability and regulatory status vary by country.
Key Sources and References
- FDA: Ozempic (semaglutide) prescribing information
- FDA: Wegovy (semaglutide) current 2026 labeling
- FDA: March 2026 approval of Wegovy HD 7.2 mg
- FDA: Mounjaro (tirzepatide) prescribing information
- FDA: Trulicity (dulaglutide) prescribing information
- NEJM: SURMOUNT-5 — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- NEJM: SURPASS-2 — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- NEJM: STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or Obesity
- PubMed: AWARD-11 weight outcomes with dulaglutide 3.0 mg and 4.5 mg
Evidence note: Direct head-to-head evidence is stronger for tirzepatide vs semaglutide 1 mg in type 2 diabetes and tirzepatide vs semaglutide 2.4 mg in obesity than for comparisons involving dulaglutide. Weight-loss percentages from separate trials should not be interpreted as perfectly interchangeable.
.png)
.png)
.png)
.png)
Comments
Post a Comment